Segmenting by application reveals that infectious-disease testing is the single largest contributor to Immunodiagnostic Device and Reagent demand, followed by oncology, cardiac, endocrine, and autoimmune niches. Infectious-disease reagents benefit from algorithm-driven repeat screening and pandemic preparedness budgets, translating into high per-patient sample volume. Oncology immunoassays exploit the shift toward protein tumor markers and PD-L1 expression tests, commanding premium pricing despite lower sample numbers. Cardiac panels, dominated by high-sensitivity troponin, exhibit steep volume growth as emergency departments shorten rule-out protocols. Endocrine assays, including TSH and fertility hormones, display stable replacement demand linked to chronic patient monitoring, whereas autoimmune markers, though lower volume, deliver double-digit revenue growth tied to lupus and rheumatoid arthritis diagnostics. Collectively, these application segments map the clinical utilization landscape, anchoring forecasts of the overall Immunodiagnostic Device and Reagent market taxonomy.